Moderna, Merck climb on collaboration with Tempus
BUZZ-Moderna, Merck climb on collaboration with Tempus ** Pharmaceutical companies Moderna MRNA.O and Merck MRK.O climb 3.25% to $193.56 and 1.46% to $144.01, respectively
** AI healthcare technology company Tempus TEM.O announces multi-year collaboration with the firms to support the potential commercialization of intismeran autogene, an experimental personalized mRNA cancer treatment developed by Moderna and Merck
** TEM says it will manage the collection and transfer of tumor tissue and blood samples needed for next-generation sequencing
** To provide sequencing services to support the therapy's design and manufacturing, subject to regulatory approvals - TEM
** The financial terms of the collaboration were not disclosed
** TEM shares down 0.71% as part of a broader decline in AI stocks
** Including last session's move, MRNA and MRK up 553.10% and 36.61% respectively
(Reporting by Jayasree Prabhu)
Recent news on Merck & Co
See all newsBrief: European Commission Approves Keytruda Plus Padcev As Perioperative Treatment For Adults With Resectable Muscle-Invasive Bladder Cancer
US STOCKS-Dow leads Wall Street higher, investors focus on healthcare stocks
Moderna recoups part of losses as BofA raises PO ahead of key cancer vaccine readout
Live Markets: Dot-com deja vu? Why Goldman Sachs is calling time on the momentum trade
Factbox: Pharma sector doubles down on AI to slash costs, timelines